Merck KGaA Selects Forest Laboratories As U.S. Partner For Alcohol Addiction Treatment
Merck KGaA today announced that is has selected Forest Laboratories, Inc. (NYSE: FRX) as its U.S. partner for future marketing and distribution of acamprosate in the United States. A drug for the treatment of alcohol addiction, acamprosate has been approved in most major European markets as well as in Latin America and Australia. It is marketed under the brand name Campral.
Lipha S.A., a pharmaceutical subsidiary of Merck KGaA in Lyon, France, expects to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) within the next few months. Based on European clinical studies, data are believed to meet FDA standards for the evaluation of safety and efficacy of acamprosate.
Alcohol abuse and alcohol addiction affect around 16 million people in the United States, representing the third largest cause of death after heart disease and cancer.
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Shimadzu Opens New Regional Office - Expanding sales and service in the Southern California region
A rapid extension of nanographene sheets from readily available hydrocarbons - Precisely controlled synthesis of structurally uniform carbon sheets could advance nanographene materials science
12 Months of Better Results from Mettler Toledo - More Than a Free Calendar
DSM and Chemtrix sign collaboration agreement in Continuous Flow Chemistry
Lucrative Growth Market: The market for silicones
Off-licenced_drug
